论文信息 - NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib - 字舞流文

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib

C. Klemke | P. Krammer | K. Gülow | J. Nicolay | D. Süss | Michael K. KieΔling | Tabea Schlör